Related Experiment Videos
Gabapentin: pharmacokinetics, efficacy, and safety
A Beydoun1, B M Uthman, J C Sackellares
1Department of Neurology, University of Michigan Medical School, Ann Arbor, USA.
Clinical Neuropharmacology
|December 1, 1995
Summary
Gabapentin, an antiepileptic drug (AED), effectively reduces partial and generalized seizures. This well-tolerated medication offers a promising new option for epilepsy treatment with a favorable pharmacokinetic profile.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Neurology
Background:
- Gabapentin is a novel antiepileptic drug (AED) with unique pharmacokinetic properties.
- Existing AEDs have limitations in efficacy and tolerability.
- Understanding gabapentin's profile is crucial for epilepsy management.
Purpose of the Study:
- To evaluate the efficacy and tolerability of gabapentin as an add-on therapy for partial-onset seizures.
- To characterize the pharmacokinetic profile of gabapentin.
- To assess potential drug-drug interactions.
Main Methods:
- Three large-scale, double-blind, placebo-controlled, parallel-group clinical trials were conducted.
- Participants received gabapentin as add-on therapy.
- Seizure frequency and adverse events were monitored.
Main Results:
- Gabapentin significantly reduced the frequency of partial seizures and secondarily generalized tonic-clonic seizures.
- The drug demonstrated a favorable pharmacokinetic profile, being renally eliminated unchanged.
- Common adverse effects included transient somnolence and dizziness; it showed minimal drug-drug interactions.
Conclusions:
- Gabapentin is an effective and well-tolerated add-on AED for partial-onset seizures.
- Its unique mechanism of action and favorable pharmacokinetics make it a valuable addition to epilepsy treatment.
- Gabapentin has the potential to improve the quality of life for patients with epilepsy.